VistaGen Therapeutics, Inc.
384 Oyster Point Boulevard
Suite 8
South San Francisco
California
94080
United States
Tel: 650-244-9990
Fax: 650-244-9979
Website: http://www.vistagen.com/
Email: rsnodgrass@vistagen.com
162 articles with VistaGen Therapeutics, Inc.
-
Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
-
Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression
1/16/2019
Developing treatments to help those struggling with depression, a disorder that can lead to suicide, has become a mission for Shawn Singh, CEO of VistaGen, and his colleagues. -
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
11/13/2018
VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.
-
VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain ...
10/6/2018
Opioids have shown tremendous efficacy in pain management. At the same time, the dangers of the addiction to the medication have become well-known in recent years as an epidemic has swept across the United States. -
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
10/3/2018
Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain
-
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
9/13/2018
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101
-
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing...
-
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
-
VistaGen Receives Notice Of Allowance From U.S. Patent And Trademark Office For U.S. Patent Regarding Methods Of Production For AV-101
10/2/2017
-
VistaGen Grants Exclusive Sublicense Of Cardiac Stem Cell Technologies To BlueRock Therapeutics
12/14/2016
-
Cash to Operate a Growing Concern for Bay Area's VistaGen
11/15/2016
-
VistaGen Therapeutics, Inc. Appoints Mark A. Mcpartland Vice President Of Corporate Development And Investor Relations
10/4/2016
-
VistaGen Therapeutics, Inc. Provides Business Outlook And Sets Corporate Milestones
9/22/2016
-
VistaGen Therapeutics, Inc. Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. As Chief Medical Officer
6/20/2016
-
VistaGen Therapeutics, Inc. Completes $10 Million Public Offering
5/13/2016
-
VistaGen Therapeutics, Inc. Announces Nasdaq Listing And Pricing Of $10.0 Million Public Offering
5/11/2016
-
VistaGen Therapeutics, Inc. Appoints Jerry Gin, Ph.D., MBA To Its Board Of Directors
3/30/2016
-
VistaGen Therapeutics, Inc. Bolsters Clinical And Regulatory Advisory Board With Appointments Of Distinguished Key Opinion Leaders In Depression
3/22/2016
-
VistaGen Therapeutics, Inc. Secures Exclusive Worldwide Commercial Rights To Three Proprietary Stem Cell Technologies From University Health Network
12/23/2015
-
VistaGen Therapeutics, Inc. Announces First Patient Dosed In NIH-Sponsored Phase 2A Study Of Orally Available AV-101 In Major Depressive Disorder
11/3/2015